Close Menu

IVF

First Genetics will market its F-Genetics NGS System and IVD assays to Russian laboratories for reproductive health testing and cancer diagnostics.

An analysis of placental, parental, and cord blood samples indicated that an uptick in chromosomal instability in cleavage-stage in vitro fertilization embryos does not persist after birth.

The firm plans to use the funding to drive sales of its preimplantation genetic screening tests and to invest in data science.

The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.

The researchers said that a faster method could avoid having to freeze embryos and as a result may improve the success rate of in vitro fertilization.

At a conference last week, researchers from Italy presented results from 73 women who had mosaic embryos transferred.

According to John Zhang, founder and CEO of the New Hope Fertility Center, universal PGS will likely increase success rates of IVF further.

A study by researchers in Italy found that preimplantation genetic diagnosis and screening combined led to more successful pregnancies per transfer but fewer women had embryos transferred.

The company feels it could be an attractive target for mergers, but is also keeping an eye out for IP acquisition options of its own.

The test uses Illumina arrays to measure genome-wide sperm DNA methylation patterns in order to predict male fertility status and resulting embryo quality.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.